All In Biotech

Drug Trial Radar · NCT06481306

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

224

Planned (sponsor's estimate)

Start

Jul 17, 2024

Primary completion

Jan 6, 2027

Study completion Nov 16, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

Conditions

  • Anemia, Sickle Cell
  • Healthy Volunteers

Interventions

  • BMS-986470Drug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

  • FamotidineDrug

    Specified dose on specified days

  • PantoprazoleDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to 26 months
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to 26 months
  3. Number of participants with AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteriaTime frame: Up to 26 months
  4. Number of participants with AEs leading to discontinuationTime frame: Up to 26 months
  5. Number of deathsTime frame: Up to 26 months
  6. Proportion of participants achieving HbF ≥ 10%Time frame: Up to 28 days after last dose
  7. Proportion of participants achieving HbF ≥ 20%Time frame: Up to 28 days after last dose
  8. Proportion of participants achieving HbF ≥ 30%Time frame: Up to 28 days after last dose

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • University of California San Diego - La Jolla

    La Jolla, California · Recruiting

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California · Recruiting

  • Yale-New Haven Hospital

    New Haven, Connecticut · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • Local Institution - 0034

    Chicago, Illinois · Not yet recruiting

  • Local Institution - 0001

    Lenexa, Kansas · Active not recruiting

  • Local Institution - 0064

    Baltimore, Maryland · Not yet recruiting

  • Local Institution - 0024

    Boston, Massachusetts · Not yet recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Local Institution - 0030

    St Louis, Missouri · Not yet recruiting

  • Local Institution - 0033

    Greenville, North Carolina · Not yet recruiting

  • Local Institution - 0028

    Cleveland, Ohio · Not yet recruiting

  • Local Institution - 0029

    Philadelphia, Pennsylvania · Not yet recruiting

  • Thomas Jefferson University - Medicine/GI and Hepatology

    Philadelphia, Pennsylvania · Recruiting

  • Local Institution - 0032

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Local Institution - 0027

    Greenville, South Carolina · Not yet recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia · Recruiting

  • Virginia Commonwealth University (VCU) Medical Center

    Richmond, Virginia · Recruiting

  • Local Institution - 0050

    Vancouver, British Columbia, Canada · Not yet recruiting

  • Local Institution - 0061

    Créteil, France · Not yet recruiting

  • Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

    Marseille, France · Recruiting

  • Hôpital Universitaire Necker Enfants Malades

    Paris, France · Recruiting

  • CHU Strasbourg-Hautepierre

    Strasbourg, France · Recruiting

  • Local Institution - 0037

    Padua, Italy · Not yet recruiting

  • Local Institution - 0009

    Verona, Italy · Not yet recruiting

  • Local Institution - 0011

    Milan, Lombardy, Italy · Not yet recruiting

  • Local Institution - 0005

    Leeds, United Kingdom · Not yet recruiting

  • Local Institution - 0047

    London, United Kingdom · Not yet recruiting

  • University Hospitals Sussex NHS Foundation Trust

    East Sussex, Brighton And Hove, United Kingdom · Recruiting

  • Local Institution - 0044

    London, Greater London, United Kingdom · Not yet recruiting

  • King's College Hospital

    London, London, City of, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.